Toll-Like Receptors Expression and Signaling in Glia Cells in Neuro-Amyloidogenic Diseases: Towards Future Therapeutic Application
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Toll-like receptors (TLRs) are known to be expressed by innate immune response cells and to play a critical role in their activation against foreign pathogens. It was recently suggested that TLRs have an important role in the crosstalk between neurons and glial cells in the central nervous system (CNS). TLR signaling was reported to be associated with a yin-yang effect in the CNS. While TLR signaling was linked to neurogenesis, it was also found to be involved in the pathogenesis of neurodegenerative diseases. This paper will focus on TLR signaling in glial cells in neurodegenerative diseases such as Alzheimer's disease, prion diseases, amyotrophic lateral sclerosis, and Parkinson's disease. Understanding the pattern of TLR signaling in the glial cells may lead to the identification of new targets for therapeutic application.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110
Inflammatory Blockade Restores Adult Hippocampal Neurogenesis
Monje, M. L., Toda, H., & Palmer, T. D. (2003) · Science · doi:10.1126/science.1088417 · Cited by 2,426
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · cited 1×
“Newborn neurons in the hippocampus and dopaminergic neurons in the substantia nigra appear to be extremely sensitive to the effects of LPS, as peripheral injection of even low levels of LPS reduces the number of these cells [71, 72].”
BackgroundLehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Currently, targeting TLRs is being used in different experimental settings, from animal model experiments to clinical trials, including several diseases, such as chronic lung disease and cancer [128].”
Staging of Alzheimer-Related Cortical Destruction
Braak, H., Braak, E., & Bohl, J. (2008) · European Neurology · doi:10.1159/000116984 · Cited by 836 · cited 2×
“[78] H.”
BackgroundPivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits
Tang, S.-C., Arumugam, T. V., Xu, X., Cheng, A., Mughal, M. R., Jo, D. G., Lathia, J. D., Siler, D. A., Chigurupati, S., Ouyang, X., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702553104 · Cited by 779
Takeuchi, H., Jin, S., Wang, J., Zhang, G., Kawanokuchi, J., Kuno, R., Sonobe, Y., Mizuno, T., & Suzumura, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600504200 · Cited by 749 · cited 1×
“In particular, LPS-activated microglia produce a large amount of glutamate, an important neurotransmitter but also a potent neurotoxin [45] and LPS injection may activate TLR4 on microglia and is linked to oligodendrocyte injury [40].”
BackgroundTLR signaling tailors innate immune responses in human microglia and astrocytes
Jack, C. S., Arbour, N., Manusow, J., Montgrain, V., Blain, M., McCrea, E., Shapiro, A., & Antel, J. P. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4320 · Cited by 734 · cited 1×
“To date, human astrocytes have been reported to express TLRs 1–5 and TLR 9 [26, 48, 49].”
BackgroundStructural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA
Liu, L., Botos, I., Wang, Y., Leonard, J. N., Shiloach, J., Segal, D. M., & Davies, D. R. (2008) · Science · doi:10.1126/science.1155406 · Cited by 733
Bal-Price, A., & Brown, G. C. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06480.2001 · Cited by 686
CD14 and Toll-Like Receptors 2 and 4 Are Required for Fibrillar Aβ-Stimulated Microglial Activation
Reed-Geaghan, E. G., Savage, J. C., Hise, A. G., & Landreth, G. E. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3158-09.2009 · Cited by 591 · cited 1×
“In microglia (Figure 1), the TLRs functionally interact with other cell surface receptors, including CD36, α6β1 integrin, CD47, and scavenger receptor A, which bind to fibrillar Aβ, to initiate the activation of intracellular signaling pathways [94, 95].”
BackgroundRole of the Toll-Like Receptor 4 in Neuroinflammation in Alzheimer’s Disease
Walter, S., Letiembre, M., Liu, Y., Heine, H., Penke, B., Hao, W., Bode, B., Manietta, N., Walter, J., Schulz-Schüffer, W., et al. (2007) · Cellular Physiology and Biochemistry · doi:10.1159/000110455 · Cited by 543
Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease
Masliah, E., Rockenstein, E., Adame, A., Alford, M., Crews, L., Hashimoto, M., Seubert, P., Lee, M., Goldstein, J., Chilcote, T., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.05.010 · Cited by 542
LAFLAMME, N., & RIVEST, S. (2001) · The FASEB Journal · doi:10.1096/fj.00-0339com · Cited by 501 · cited 1×
“Constitutive expression of TLRs is primarily in microglia and largely restricted to the circumventricular organs (CVOs) and meninges, areas with direct access to the circulation, although they may be expressed at lower levels in other regions, too [28, 38, 39].”
BackgroundA Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501
Role of toll-like receptor signalling in A uptake and clearance
Tahara, K., Kim, H.-D., Jin, J.-J., Maxwell, J. A., Li, L., & Fukuchi, K.-I. (2006) · Brain · doi:10.1093/brain/awl249 · Cited by 493
Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B. (2005) · Journal of Neuroinflammation · doi:10.1186/1742-2094-2-14 · Cited by 414
Chakravarty, S., & Herkenham, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4268-04.2005 · Cited by 396
The LPS receptor (CD14) links innate immunity with Alzheimer's disease
Fassbender, K., Walter, S., Kühl, S., Landmann, R., Ishii, K., Bertsch, T., Stalder, A. K., Muehlhauser, F., Liu, Y., Ulmer, A. J., et al. (2004) · The FASEB Journal · doi:10.1096/fj.03-0364fje · Cited by 307 · cited 2×
“An examination of TLR expression in the brain revealed that there was increased expression of CD14, TLR2, and TLR4 in AD human brains and animal models [41, 84–86].”
BackgroundRichard, K. L., Filali, M., Préfontaine, P., & Rivest, S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1146-08.2008 · Cited by 298
Extracellular mutant SOD1 induces microglial‐mediated motoneuron injury
Zhao, W., Beers, D. R., Henkel, J. S., Zhang, W., Urushitani, M., Julien, J., & Appel, S. H. (2010) · Glia · doi:10.1002/glia.20919 · Cited by 288
Xie, Z., Wei, M., Morgan, T. E., Fabrizio, P., Han, D., Finch, C. E., & Longo, V. D. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03484.2002 · Cited by 272
Nguyen, M. D., D'Aigle, T., Gowing, G., Julien, J.-P., & Rivest, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.4786-03.2004 · Cited by 248 · cited 1×
“[117] activated the innate immune response in mSOD1 mice.”
BackgroundRogers, J., & Lue, L.-F. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00040-7 · Cited by 236 · cited 2×
“This striking difference in subcellular localization of TLRs between microglia and astrocyte may relate to the difference in phagocytic and antigen processing properties of these cells [29–32].”
BackgroundThe lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery
Dutta, G., Zhang, P., & Liu, B. (2008) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00616.x · Cited by 235 · cited 1×
“One of the Parkinson’s disease animal models is composed of an intranigral LPS injection, which stimulates dopaminergic cell death [123].”
BackgroundMyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival
Kim, Y., Zhou, P., Qian, L., Chuang, J.-Z., Lee, J., Li, C., Iadecola, C., Nathan, C., & Ding, A. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070868 · Cited by 234
Screening of innate immune receptors in neurodegenerative diseases: A similar pattern
Letiembre, M., Liu, Y., Walter, S., Hao, W., Pfander, T., Wrede, A., Schulz-Schaeffer, W., & Fassbender, K. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.08.018 · Cited by 228
Intrahippocampal LPS injections reduce Aβ load in APP+PS1 transgenic mice
DiCarlo, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00292-5 · Cited by 223
Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease
Farfara, D., Lifshitz, V., & Frenkel, D. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00314.x · Cited by 216 · cited 1×
“While the role of inflammation in disease progression in AD is not fully understood, an increased amount of findings suggest that Aβ deposition and NFT activate a potentially pathological innate immune response in the disease [81].”
BackgroundSelf-citationChen, K., Iribarren, P., Hu, J., Chen, J., Gong, W., Cho, E. H., Lockett, S., Dunlop, N. M., & Wang, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508125200 · Cited by 214 · cited 2×
“In addition, phagocytosis is stimulated by TLR activation, which may be particularly relevant to the clearance of bacteria as well as aggregated or abnormal proteins such as amyloid fibers from the CNS [35, 36] (Figure 1).”
BackgroundPathogenesis of prion diseases: current status and future outlook
Aguzzi, A., & Heikenwalder, M. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1492 · Cited by 207 · cited 2×
“Furthermore, treatment with synthetic oligodeoxynucleotides that contain cytosine phosphate guanosine (CpG-ODN) motifs, known to bind to TLR9, have been suggested as possible treatment for prion diseases in a mouse model, by delaying the disease onset [105, 107].”
BackgroundInnate immune receptor expression in normal brain aging
Letiembre, M., Hao, W., Liu, Y., Walter, S., Mihaljevic, I., Rivest, S., Hartmann, T., & Fassbender, K. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.01.004 · Cited by 175 · cited 2×
“An examination of TLR expression in the brain revealed that there was increased expression of CD14, TLR2, and TLR4 in AD human brains and animal models [41, 84–86].”
BackgroundPostexposure prophylaxis against prion disease with a stimulator of innate immunity.
Sethi, S., Lipford, G., Wagner, H., & Kretzschmar, H. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09513-2 · Cited by 138
Doi, Y., Mizuno, T., Maki, Y., Jin, S., Mizoguchi, H., Ikeyama, M., Doi, M., Michikawa, M., Takeuchi, H., & Suzumura, A. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090418 · Cited by 135
Arai, H., Furuya, T., Yasuda, T., Miura, M., Mizuno, Y., & Mochizuki, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407328200 · Cited by 122 · cited 1×
“In this model, microglial cells are activated, and demonstrate an upregulation of proinflammatory cytokines and free radical production [124, 125].”
BackgroundIribarren, P., Chen, K., Hu, J., Gong, W., Cho, E. H., Lockert, S., Uranchimeg, B., & Wang, J. M. (2005) · The FASEB Journal · doi:10.1096/fj.05-4578fje · Cited by 92
Frank, S., Copanaki, E., Burbach, G. J., Müller, U. C., & Deller, T. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.01.075 · Cited by 86 · cited 1×
“Plaque-associated microglia exhibit elevated mRNA levels for TLR2, 4, 5, 7, 9 [87] (Figure 1).”
BackgroundPrion pathogenesis in the absence of Toll-like receptor signalling
Prinz, M., Heikenwalder, M., Schwarz, P., Takeda, K., Akira, S., & Aguzzi, A. (2003) · The EMBO Reports · doi:10.1038/sj.embor.embor731 · Cited by 85 · cited 1×
“Nevertheless, MyD88 knockout mice inoculated with prions have not shown different prion pathogenesis kinetics from the control mice, suggesting that TLRs 1, 2, 6, and 9 signal through the MyD88 pathway and are not involved in the progression of the disease [105, 106] (Figure 1).”
BackgroundAccelerated prion disease pathogenesis in toll-like receptor 4 signaling-mutant mice.
Spinner, D. S., Cho, I. S., Park, S. Y., Kim, J. I., Meeker, H. C., Ye, X., LaFauci, G., Kerr, D. J., Flory, M. J., Kim, B. S., et al. (2008) · Journal of Virology · doi:10.1128/jvi.00522-08 · Cited by 57 · cited 1×
“This indicates an involvement of TLR4 in the progression of the disease [102].”
Background
Cited by
Verkhratsky, A., & Nedergaard, M. (2018) · Physiological Reviews · doi:10.1152/physrev.00042.2016 · Cited by 1,678
Obesity, Inflammation, Toll-Like Receptor 4 and Fatty Acids
Rogero, M., & Calder, P. (2018) · Nutrients · doi:10.3390/nu10040432 · Cited by 706
Toll-like receptors in immunity and inflammatory diseases: Past, present, and future
Vijay, K. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.03.002 · Cited by 643
Brain-Gut-Microbiota Axis in Parkinson’s Disease
Mulak, A. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i37.10609 · Cited by 583
Mechanisms of Aβ Clearance and Degradation by Glial Cells
Ries, M., & Sastre, M. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00160 · Cited by 527
Metadata
- Authors
- Trudler, D., Farfara, D., & Frenkel, D.
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2010
- Volume
- 2010
- Pages
- 1-12
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- OpenAlex
- W1980452558
- Cited by
- 118
- References
- 41
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.